Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.44 |
| ▸ | TACR3 | P29371 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600403 | 0.93 | HCRTR1 (0.45) | HCRTR1HCRTR2TACR3CYP1A2CYP2C9 | |
| SCHEMBL601360 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2TACR3CYP1A2CYP2C9 | |
| SCHEMBL599430 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2TACR3CYP1A2CYP2C9 | |
| SCHEMBL599435 | 0.83 | HCRTR2 (0.43) | HCRTR1HCRTR2KCNH2MCHR1GRM5 | |
| SCHEMBL30794977 | 0.83 | HCRTR2 (0.43) | HCRTR1HCRTR2KCNH2MCHR1GRM5 | |
| SCHEMBL600383 | 0.82 | HCRTR1 (0.43) | HCRTR1HCRTR2MCHR1 | |
| SCHEMBL30795828 | 0.81 | HCRTR2 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL600384 | 0.81 | HCRTR2 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL602090 | 0.81 | HCRTR1 (0.45) | HCRTR1HCRTR2TACR3CYP1A2CYP2C9 | |
| SCHEMBL599416 | 0.81 | HCRTR1 (0.45) | HCRTR1HCRTR2TACR3CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | GRM5, GRIK5, GRM2 | HCRTR1 199/4885HCRTR2 102/4885TACR3 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.